Loading...
Market
FDA issues final diversity guidance by end of Q1 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and publications
Story
FDA Issues Long-Awaited Draft Guidance to Improve Diversity in Clinical Trials for Medical Device Makers
Jun 26, 2024, 02:56 PM
The U.S. Food and Drug Administration (FDA) has issued long-awaited draft guidance to improve diversity in clinical trials. Released six months later than expected, the guidance aims to enhance the representation of racial, ethnic, and other underrepresented groups in clinical studies. This initiative is designed to yield a better understanding of treatment effects, improve clinical trial results, and increase trust and participation among diverse populations. The guidance provides detailed instructions for medical product sponsors and medical device makers on how to submit Diversity Action Plans, which are now required for certain clinical studies.
View original story
Similar markets
Yes • 50%
No • 50%
Approved • 25%
Approved with Conditions • 25%
Not Approved • 25%
Decision Delayed • 25%
Implement similar rules • 25%
Rescind existing rules • 25%
No changes • 25%
Other actions • 25%
Yes • 50%
No • 50%
Centers for Medicare & Medicaid Services (CMS) • 25%
Food and Drug Administration (FDA) • 25%
Department of Health and Human Services (HHS) • 25%
Other • 25%
Completely ended • 25%
Partially scaled back • 25%
Unchanged • 25%
Expanded • 25%
